Loading organizations...

§ Private Profile · Aliso Viejo, CA, USA
Medical device developer creating wireless, catheter-free urodynamic systems for clinicians treating lower urinary tract conditions.
Bright Uro is an Irvine, California-based medical technology company that develops wireless, catheter-free devices for the diagnosis and monitoring of lower urinary tract conditions. The seed-stage firm's lead product, the Glean Urodynamic System, wirelessly quantifies urinary tract pressure characteristics to address conditions like urinary incontinence, which affects over 50 percent of women and 25 percent of men over the age of 65 in the United States. In March 2025, the enterprise submitted an FDA 510(k) clearance application for the Glean system to facilitate future commercialization efforts across the broader urology and digital health sectors. The company operates with early strategic equity investment backing from Laborie Medical Technologies, a transaction supported by Laborie executive Michael Frazzette, while product development is led by Dr. Suranjan Roychowdhury. Bright Uro was originally founded in 2021 by Derek Herrera.
Bright Uro has raised $33.0M across 3 funding rounds.
Bright Uro has raised $33.0M in total across 3 funding rounds.
Bright Uro has raised $33.0M across 3 funding rounds. Most recently, it raised $23.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 30, 2023 | $23M Series A | Michael Frazzette | — | Announced |
| Jun 9, 2022 | $6M Grant | — | Fred Moll, M.D, Sherman Williams II, National Institutes OF Health | Announced |
| Jun 1, 2022 | $4M Seed | — | Johnson & Johnson Innovation, Sonder Capital | Announced |
Bright Uro is a medical technology company that develops a wireless, catheter-free urodynamics system called the Glean Urodynamics System, designed for non-invasive bladder function monitoring. It serves urologists, urogynecologists, and healthcare professionals by providing a more comfortable, accurate, and streamlined alternative to traditional invasive catheter-based urodynamic testing. This innovation improves patient experience, expands access to testing in standard clinical exam rooms, and enhances diagnostic accuracy for lower urinary tract symptoms (LUTS) such as urinary incontinence and overactive bladder[1][2][4].
Founded in 2021, Bright Uro emerged from foundational research at Cleveland Clinic, with its CEO Derek Herrera leading the company. The idea originated to address the discomfort, infection risks, and diagnostic limitations of conventional urodynamic studies. Early traction includes FDA clearance of the Glean system and partnerships with leading institutions like Cleveland Clinic and Laborie Medical Technologies, which invested in Bright Uro to accelerate its market impact[2][3][4].
Bright Uro rides the trend toward minimally invasive, patient-centric medical diagnostics enhanced by digital health and cloud technologies. The timing is critical as the aging population increases demand for better management of LUTS, affecting millions, especially older adults. Market forces favor innovations that reduce healthcare costs, improve patient comfort, and provide more reliable physiological data. Bright Uro’s technology influences the broader urology ecosystem by setting new standards for ambulatory urodynamics and enabling more personalized, data-driven care[3][4].
Bright Uro is poised for growth as it expands clinical adoption and integrates advanced data science into its platform. Future trends shaping its journey include the rise of remote patient monitoring, AI-driven diagnostics, and increasing emphasis on outpatient care models. Its influence is likely to evolve from a disruptive startup to a key player in urology diagnostics, potentially broadening into related fields such as urogynecology and chronic bladder condition management. Continued partnerships with major medical institutions and technology investors will support its mission to transform LUTS care globally[3][4][5].
Bright Uro has raised $33.0M in total across 3 funding rounds.
Bright Uro's investors include Michael Frazzette, Fred Moll, M.D, Sherman Williams II, National Institutes of Health, Johnson & Johnson Innovation, Sonder Capital.